Bookmark and Share

Notice: On March 31, it was announced that Statalist is moving from an email list to a forum. The old list will shut down on April 23, and its replacement, statalist.org is already up and running.


[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

Re: st: pk analysis suite: elementary questions about -pkequiv-, -pkcross-, and -pkshape-


From   "Joseph Coveney" <jcoveney@bigplanet.com>
To   <statalist@hsphsun2.harvard.edu>
Subject   Re: st: pk analysis suite: elementary questions about -pkequiv-, -pkcross-, and -pkshape-
Date   Sun, 21 Feb 2010 13:27:41 +0900

Michael McCulloch wrote:

Thank you kindly for the very helpful response and example.
You write "the potential for carryover effects (by whatever name) to  
confound crossover studies
is often more serious with outcomes other than chemical  
concentrations." Might you be able to recommend some reading (either  
published or online tutorials) on this issue in crossover studies?

--------------------------------------------------------------------------------

Outside of the biopharmaceutics-specific literature, the following reference
would be a good place to start:

Stephen J. Senn, _Cross-over Trials in Clinical Research_  Second Edition.
Chichester: John Wiley & Sons, 2002.


Online, there is a paper delivered at a SAS meeting some years ago:

http://www2.sas.com/proceedings/sugi24/Posters/p221-24.pdf

Its title comes across as a bit too negative, but the paper does touch on some
of the pitfalls in design and execution of a crossover study.

Joseph Coveney


*
*   For searches and help try:
*   http://www.stata.com/help.cgi?search
*   http://www.stata.com/support/statalist/faq
*   http://www.ats.ucla.edu/stat/stata/


© Copyright 1996–2014 StataCorp LP   |   Terms of use   |   Privacy   |   Contact us   |   Site index